{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:11:39Z","timestamp":1791223899493,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.encep.2015.09.005","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T21:26:16Z","timestamp":1445808376000},"page":"541-549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacit\u00e9 et tol\u00e9rance \u00e0 long terme de la lurasidone dans la prise en charge de la schizophr\u00e9nie"],"prefix":"10.1016","volume":"41","author":[{"given":"L.","family":"Samalin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Honciuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-M.","family":"Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.encep.2015.09.005_bib0145","doi-asserted-by":"crossref","first-page":"g1173","DOI":"10.1136\/bmj.g1173","article-title":"Management of psychosis and schizophrenia in adults: summary of updated NICE guidance","volume":"348","author":"Kuipers","year":"2014","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.encep.2015.09.005_bib0150","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"Guidelines for biological treatment of schizophrenia, part 1: update 2012\u00a0on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.encep.2015.09.005_bib0155","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2012.739708","article-title":"Guidelines for biological treatment of schizophrenia, part 2: update 2012\u00a0on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects","volume":"14","author":"Hasan","year":"2013","journal-title":"World J Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.encep.2015.09.005_bib0160","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology","volume":"25","author":"Barnes","year":"2011","journal-title":"J Psychopharmacol"},{"issue":"1","key":"10.1016\/j.encep.2015.09.005_bib0165","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009\u00a0Schizophrenia PORT Psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr Bull"},{"issue":"2","key":"10.1016\/j.encep.2015.09.005_bib0170","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.encep.2015.09.005_bib0175","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/schbul\/sbq042","article-title":"Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons","volume":"38","author":"Rummel-Kluge","year":"2012","journal-title":"Schizophr Bull"},{"issue":"2\u20133","key":"10.1016\/j.encep.2015.09.005_bib0180","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.encep.2015.09.005_bib0185","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/TCRM.S12701","article-title":"Clinical potential of lurasidone in the management of schizophrenia","volume":"7","author":"Samalin","year":"2011","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.encep.2015.09.005_bib0190","series-title":"Drug Approval Package Latuda (lurasidone hydrochloride) Tablets","year":"2010"},{"key":"10.1016\/j.encep.2015.09.005_bib0195","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2147\/NDT.S68417","article-title":"The clinical utility of lurasidone in schizophrenia: patient consideration","volume":"11","author":"Harvey","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.encep.2015.09.005_bib0200","series-title":"Commission de la Transparence\u00a0: Latuda","year":"2014"},{"key":"10.1016\/j.encep.2015.09.005_bib0205","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.encep.2014.10.009","article-title":"Efficacit\u00e9 et tol\u00e9rance \u00e0 court terme de la lurasidone dans la prise en charge de la schizophr\u00e9nie","volume":"40","author":"Samalin","year":"2014","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2015.09.005_bib0210","series-title":"Latuda (lurasidone HCl)\u00a0: monographie du produit","year":"2014"},{"issue":"10","key":"10.1016\/j.encep.2015.09.005_bib0215","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1517\/17460441.2013.815163","article-title":"The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia","volume":"8","author":"Tarazi","year":"2013","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"10.1016\/j.encep.2015.09.005_bib0220","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.encep.2015.09.005_bib0225","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hup.2338","article-title":"Effect of food on the pharmacokinetics of lurasidone: results of two randomised, open-label, crossover studies","volume":"28","author":"Preskorn","year":"2013","journal-title":"Hum Psychopharmacol"},{"issue":"1","key":"10.1016\/j.encep.2015.09.005_bib0230","first-page":"S372","article-title":"A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia","volume":"29","author":"Tandon","year":"2014","journal-title":"Eur Psychiatry"},{"issue":"3","key":"10.1016\/j.encep.2015.09.005_bib0235","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/YIC.0b013e32835281ef","article-title":"Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study","volume":"27","author":"Citrome","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.encep.2015.09.005_bib0240","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2013.03.013","article-title":"Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study","volume":"147","author":"Loebel","year":"2013","journal-title":"Schizophr Res"},{"issue":"5","key":"10.1016\/j.encep.2015.09.005_bib0245","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4088\/JCP.12m08084","article-title":"Effectiveness of lurasidone for patients with schizophrenia following 6\u00a0weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study","volume":"74","author":"Stahl","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.encep.2015.09.005_bib0250","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4088\/JCP.12m07992","article-title":"Effectiveness of lurasidone in patient with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study","volume":"74","author":"McEvoy","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.encep.2015.09.005_bib0255","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1017\/S109285291300093X","article-title":"Effectiveness of lurasidone in patient with schizophrenia or schizoaffective disorder switched from other antipsychotics: a 6-month, open-label, extension study","volume":"19","author":"Citrome","year":"2014","journal-title":"CNS Spectr"},{"issue":"11","key":"10.1016\/j.encep.2015.09.005_bib0260","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.euroneuro.2013.08.003","article-title":"Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo-and active-controlled study followed by a 6-month double-blind extension","volume":"23","author":"Harvey","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1\u20133","key":"10.1016\/j.encep.2015.09.005_bib0265","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.schres.2015.06.008","article-title":"Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study","volume":"166","author":"Harvey","year":"2015","journal-title":"Schizophr Res"},{"issue":"4","key":"10.1016\/j.encep.2015.09.005_bib0270","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/nedt.2006.2.4.531","article-title":"Cognitive deficits and functional outcome in schizophrenia","volume":"2","author":"Bowie","year":"2006","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.encep.2015.09.005_bib0275","series-title":"The Maudsley Prescribing Guidelines","author":"Taylor","year":"2009"},{"issue":"11","key":"10.1016\/j.encep.2015.09.005_bib0140","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.drudis.2014.07.010","article-title":"Bipolar disorder: recent clinical trials and emerging therapies for depressive episodes and maintenance treatment","volume":"19","author":"Garay","year":"2014","journal-title":"Drug Discov Today"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700615001669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700615001669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T08:26:58Z","timestamp":1537259218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700615001669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0013700615001669"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2015.09.005","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacit\u00e9 et tol\u00e9rance \u00e0 long terme de la lurasidone dans la prise en charge de la schizophr\u00e9nie","name":"articletitle","label":"Article Title"},{"value":"L'Enc\u00e9phale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.encep.2015.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 L\u2019Enc\u00e9phale, Paris. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}